![Debra Stephanie Barker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Debra Stephanie Barker
Hoofd Techniek/Wetenschap/O&O bij DESTINY PHARMA PLC
Vermogen: 24 296 $ op 31-12-2024
Profiel
Debra Stephanie Barker is currently serving as a Non-Executive Director at CureVac SE.
She also holds the position of Senior Independent Non-Executive Director at Destiny Pharma Plc, Non-Executive Director at BerGenBio ASA, Senior Independent Non-Executive Director at Arix Bioscience Plc, Director at Hutman Diagnostics AG, Senior Independent Director at Arix Bioscience, and Member-Supervisory Board at CureVac NV.
In her former roles, Dr. Barker worked as the Head of Development, Anti-Infectives & Immunology at Novartis AG and as the Chief Medical & Development Officer at Spexis Ltd.
from 2017 to 2018.
Dr. Barker completed her graduate degree at King's College London and holds a doctorate from Queens' College Cambridge.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CUREVAC N.V.
0.00% | 15-03-2024 | 7 125 ( 0.00% ) | 24 296 $ | 31-12-2024 |
Actieve functies van Debra Stephanie Barker
| Bedrijven | Functie | Begin |
|---|---|---|
| BERGENBIO ASA | Directeur/Bestuurslid | 13-03-2019 |
| DESTINY PHARMA PLC | Hoofd Techniek/Wetenschap/O&O | 01-10-2023 |
| CUREVAC N.V. | Directeur/Bestuurslid | 22-06-2022 |
| ARIX BIOSCIENCE PLC | Directeur/Bestuurslid | 10-08-2022 |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Directeur/Bestuurslid | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Directeur/Bestuurslid | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Directeur/Bestuurslid | 01-08-2022 |
Eerdere bekende functies van Debra Stephanie Barker
| Bedrijven | Functie | Einde |
|---|---|---|
| SPEXIS AG | Hoofd Techniek/Wetenschap/O&O | 31-12-2018 |
| NOVARTIS AG | Corporate Officer/Principal | - |
Opleiding van Debra Stephanie Barker
| Queens' College Cambridge | Doctorate Degree |
| King's College London | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 5 |
|---|---|
| SPEXIS AG | Health Technology |
| NOVARTIS AG | Health Technology |
| BERGENBIO ASA | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| CUREVAC N.V. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
Arix Bioscience Plc
 Arix Bioscience Plc Investment ManagersFinance Arix Bioscience Plc is a global venture capital company. It engages in sourcing, financing, and developing healthcare and life science businesses globally. The firm's portfolio includes companies that specializes in different therapeutic areas such as anti-infectives, immunology and inflammation, rare diseases, and oncology. The company was founded by Jonathan M. Peacock, Joseph Anderson, and Christopher Thomas Evans on September 15, 2015 and is headquartered in London, the United Kingdom. | Finance |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
